Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry

Summary

A score that can accurately determine the risk of major bleeding during anticoagulant therapy may help to make decisions on anticoagulant use. RIETE is an ongoing registry of consecutive patients with acute venous thromboembolism (VTE). We composed a score to predict the risk for major bleeding within three months of anticoagulant therapy. Of 19,274 patients enrolled, 13,057 (67%) were randomly assigned to the derivation sample, 6,572 to the validation sample. In the derivation sample 314 (2.4%) patients bled (fatal bleeding, 105). On multivariate analysis, age >75 years, recent bleeding, cancer, creatinine levels >1.2 mg/dl, anemia, or pulmonary embolism at baseline were independently associated with an increased risk for major bleeding. A score was composed assigning 2 points to recent bleeding, 1.5 to abnormal creatinine levels or anemia, 1 point to the remaining variables. In the derivation sample 2,654 (20%) patients scored 0 points (low risk); 9,645 (74%) 1–4 points (intermediate); 758 (5.8%) >4 points (high risk). The incidences of major bleeding were: 0.3% (95% confidence interval [CI]: 0.1–0.6), 2.6% (95% CI: 2.3–2.9), and 7.3% (95% CI: 5.6–9.3), respectively. The likelihood ratio test was:0.14 (95% CI:0.07–0.27) for patients at low risk;2.96 (95% CI:2.18–4.02) for those at high risk. In the validation sample the incidence of major bleeding was:0.1%,2.8%,and 6.2%,respectively. In conclusion, a risk score based on six variables documented at entry can identify VTE patients at low, intermediate, or high risk for major bleeding during the first three months of therapy.

Keywords

Venous thromboembolism - bleeding complications - prediction

^* A full list of RIETE investigators is given in the appendix.

• References

• 1 Nieuwenhuis K. et al. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78: 2337-2343.
• 2 Linkins LA. et al. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893-900.
• 3 Kearon C. Long-term management of patients after venous thromboembolism. Circulation. 2004 110. suppl I I-10-I-18.
• 4 Ellis MH. et al. Hemorrhagic complications in patients treated with anticoagulant doses of low molecular weight heparin (Enoxaparin) in routine hospital practice. Clin Appl Thromb Haemost 2006; 12: 199-204.
• 5 Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-152.
• 6 Kuijer PM. et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159: 457-460.
• 7 Blanco-Molina A. et al. and the RIETE Investigators. Venous Thromboembolism during pregnancy or postpartum: Findings from the RIETE Registry. Thromb Haemost 2007; 97: 186-190.
• 8 Arcelus JI. et al. and the RIETE Investigators. Clinical presentation and time-course of postoperative venous thromboembolism: Results from the RIETE Registry. Thromb Haemost 2008; 99: 546-551.
• 9 Lobo JL. et al. for the RIETE Investigators. Clinical Syndromes and Clinical Outcome in Patients with Pulmonary Embolism. Findings from the RIETE Registry. Chest 2006; 130: 1817-1822.
• 10 Nieto JA. et al. for the RIETE Investigators. Acute venous thromboembolism in patients with recent major bleeding. The influence of the site of bleeding and the time elapsed on outcome. J Thromb Haemost 2006; 04: 2367-2372.
• 11 Monreal M. et al. for the RIETE Investigators. Pulmonary embolism in patients with chronic obstructive pulmonary disease or congestive heart failure. Findings from the RIETE Registry. Am J Med 2006; 119: 851-858.
• 12 The Columbus Investigators. Low molecular weight heparin is an effective and safe treatment for deep vein thrombosis and pulmonary embolism. N Engl J Med 1997; 337: 657-662.
• 13 Gould MK. et al. Low molecular weight heparins compared with unfractionated heparin for the treatment of acute deep venous thrombosis: A meta-analysis of randomized controlled trials. Ann Intern Med 1999; 130: 800-809.
• 14 Schulman S, Ögren M. New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism. Thromb Haemost 2006; 96: 258-266.
• 15 Beyth RI. et al. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomised, controlled trial. Ann Intern Med 2003; 133: 687-695.
• 16 Lim W. et al. Meta-analysis: Low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 673-684.
• 17 López-Jiménez L. et al. for the RIETE investigators. Venous thromboembolism in very elderly patients: Findings from a prospective Registry (RIETE). Haematologica 2006; 91: 1046-1051.
• 18 Falgà C. et al. for the RIETE Investigators. Clinical Outcome of Patients with Venous Thromboembolism and Renal Insufficiency. Findings from the RIETE Registry. Thromb Haemost 2007; 98: 771-776.
• 19 Shireman TI. et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006; 130: 1390-1396.
• 20 Gage BF. et al. Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713-719.